PORTLAND, Oregon., February 7, 2022 /PRNewswire/ — Allied Market Research has released a report titled, Idiopathic Pulmonary Fibrosis Market By Drug Type (Nintedanib and Pirfenidone) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Vendors): Global Opportunities Analysis and Industry Forecast, 2021-2030. » According to the report, the global Idiopathic Pulmonary Fibrosis industry generated $3.12 billion in 2020, and should reach $6.16 billion by 2030 growing at a CAGR of 7.0% from 2021 to 2030.

For a good perspective and competitive insights, get a sample report on: https://www.alliedmarketresearch.com/request-sample/4407

Drivers, constraints and opportunities

Rising incidence of cancer globally, favorable reimbursement policies provided by manufacturers and insurers, and increasing smoking habits are driving the growth of the global idiopathic pulmonary fibrosis market. However, the unavailability of suitable treatment options is restraining the growth of the market. On the other hand, the increase in the number of drugs in development and the untapped potential in developing countries offer new opportunities in the years to come.

Covid-19 scenario

  • There has been a decline in the number of visits by patients with idiopathic pulmonary fibrosis to hospitals and clinics for treatment of idiopathic pulmonary fibrosis (IPF) to avoid cross-contamination. Additionally, there has been a postponement of elective surgeries to care for Covid-infected patients.
  • The Idiopathic Pulmonary Fibrosis Market has been negatively impacted by the outbreak of the Covid-19 pandemic. Demand for drugs has declined from retail pharmacies and online providers due to reduced therapy sessions and treatments.

The pirfenidone segment will continue its leading status during the forecast period

Based on drug type, pirfenidone segment accounted for the highest share in 2020, holding about three-quarters of the global idiopathic pulmonary fibrosis market, and is expected to maintain its leading status during the forecast period. . Moreover, this segment is expected to exhibit the highest CAGR of 7.2% from 2021 to 2030. This is due to the increase in adoption of pirfenidone drugs such as Esbriet and Pirespa across the globe. The research also analyzes the nintedanib segment.

Do you have a specific question or requirement? Ask our industry expert: https://www.alliedmarketresearch.com/purchase-enquiry/4407

The retail pharmacy segment will maintain its leading position during the forecast period

Based on distribution channel, the retail pharmacy segment accounted for the highest share in 2020, contributing almost half of the global idiopathic pulmonary fibrosis market, and is expected to maintain its leading position during the period. forecast. This is attributed to the rapidly increasing rate of idiopathic pulmonary fibrosis among the geriatric population, technological advancements, and lifestyle changes around the world. However, the online vendor segment is expected to show the highest CAGR of 8.5% from 2021 to 2030. This is due to the offers and discounts offered by the vendors and the availability of different types of drugs in a single platform. .

North America maintain its lead in terms of turnover by 2030

Based on the region, North America contributed the highest market share in 2020, holding more than two-fifths of the global idiopathic pulmonary fibrosis market, and is expected to maintain its revenue lead by 2030. This is attributed to the high expenditure in R&D, the presence of major players and the availability of their products, and a well-established healthcare infrastructure in the region. However, Asia Pacific is expected to show the fastest CAGR of 8.9% during the forecast period, owing to improved R&D facilities and rapidly changing economic conditions.

Main market players

  • Astra Zeneca Plc
  • Biogene Inc.
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • FibroGen, Inc.
  • Therapeutic Mission
  • GNI Group Ltd.
  • Galapagos NV
  • biogenic
  • Bristol-Myers Squibb Company
  • Shiongi Co.Ltd.

Avenue Basic Plan | Access to the library | 1 year subscription |

Sign up for the Avenue subscription to access over 12,000 company profiles and over 2,000 niche market research reports on $699 per month, per seat. For one year, the customer must purchase a minimum 2-seat plan.

14-day free trial request: https://www.alliedmarketresearch.com/avenue/trial/starter

“We have also published some syndicated market studies in the same field that you may be interested in. Below is the title of the report for your reference, considering the impact of Covid-19 on this market which will help you to assess the aftereffects of the pandemic on the short and long term growth trends of this market.”

Reports on trends in the healthcare industry (book now with 10% discount):

Virtual Reality in Healthcare Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Hydrocephalus Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Optical Imaging Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Plant Tissue Culture Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Surgical Robotics Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Nephrology Drugs Market – Opportunity Analysis and Industry Forecast, 2020-2030

Telemedicine Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Pharmaceutical Suppositories Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Enteric Softgels Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

Over-the-Counter Testing Market – Global Opportunity Analysis and Industry Forecast, 2020-2030

About Us

Allied Market Research (AMR) is a full-service market research and business advisory division of Allied Analytics LLP based in Portland, OR. Allied Market Research provides global corporations as well as small and medium enterprises with unrivaled quality of “market research reports” and “Business Intelligence solutions”. AMR has a focused vision to provide business insights and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market area.

Pawan Kumar, CEO of Allied Market Research, leads the organization in delivering high quality data and insights. We maintain professional relationships with various companies which helps us to extract market data which helps us to generate accurate research data tables and confirm the utmost accuracy of our market predictions. All data presented in the reports we publish are drawn from primary interviews with senior managers of large companies in the relevant field. Our secondary data sourcing methodology includes extensive online and offline research and discussions with knowledgeable industry professionals and analysts.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
United States/Canada (Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
hong kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
The Web: https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow us on LinkedIn: https://www.linkedin.com/showcase/life-sciences-industry-research/

SOURCE Allied Market Research